- Home
- FOA vs PBYI Comparison
FOA vs PBYI Comparison
Compare FOA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FOA
- PBYI
- Stock Information
- Founded
- FOA 2013
- PBYI 2010
- Country
- FOA United States
- PBYI United States
- Employees
- FOA N/A
- PBYI N/A
- Industry
- FOA Finance Companies
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- FOA Finance
- PBYI Health Care
- Exchange
- FOA Nasdaq
- PBYI Nasdaq
- Market Cap
- FOA 284.3M
- PBYI 171.7M
- IPO Year
- FOA N/A
- PBYI N/A
- Fundamental
- Price
- FOA $25.95
- PBYI $4.64
- Analyst Decision
- FOA Buy
- PBYI Strong Buy
- Analyst Count
- FOA 2
- PBYI 1
- Target Price
- FOA $27.50
- PBYI $7.00
- AVG Volume (30 Days)
- FOA 112.7K
- PBYI 648.1K
- Earning Date
- FOA 11-05-2025
- PBYI 11-06-2025
- Dividend Yield
- FOA N/A
- PBYI N/A
- EPS Growth
- FOA N/A
- PBYI 434.29
- EPS
- FOA 7.10
- PBYI 0.97
- Revenue
- FOA $527,520,999.00
- PBYI $238,062,000.00
- Revenue This Year
- FOA $21.89
- PBYI N/A
- Revenue Next Year
- FOA $10.33
- PBYI N/A
- P/E Ratio
- FOA $3.62
- PBYI $4.76
- Revenue Growth
- FOA 46.94
- PBYI 8.63
- 52 Week Low
- FOA $10.00
- PBYI $2.32
- 52 Week High
- FOA $32.40
- PBYI $6.07
- Technical
- Relative Strength Index (RSI)
- FOA 48.46
- PBYI 49.99
- Support Level
- FOA $24.47
- PBYI $4.49
- Resistance Level
- FOA $27.12
- PBYI $5.22
- Average True Range (ATR)
- FOA 1.46
- PBYI 0.26
- MACD
- FOA -0.31
- PBYI -0.12
- Stochastic Oscillator
- FOA 33.13
- PBYI 22.33
About FOA Finance of America Companies Inc.
Finance of America Companies Inc is a financial services holding company that, through its operating subsidiaries, is a modern retirement solutions platform that provides customers with access to a range of retirement offerings centered on the home. In addition, FoA offers capital markets and portfolio management capabilities to optimize the distribution of its originated loans to investors. It operates through two segments: Retirement Solutions and Portfolio Management. It generates the majority of its revenue from Retirement Solutions.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.